• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BGT
Click for more information
0.00% 3.6¢

BIO-GENE TECHNOLOGY LTD - Announcements

Market Cap $8.859M  ! watchlist Created with Sketch. Add to my watchlist

Bio-Gene Technology Limited is an Australia-based agriculture technology development... Bio-Gene Technology Limited is an Australia-based agriculture technology development company enabling the next generation of novel insecticides derived from nature to achieve high impact globally. Its technology is based on compounds with a novel mode of action proven to overcome insecticide resistance with minimal impact on human health and the environment. The Company’s technology provides multiple potential new solutions in applications across crop protection, grain storage, public health, and consumer products. It is developing and commercialising a broad portfolio of targeted insect control and pest management solutions. The Company's lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a chemically synthesized product based on flavesone. Qcide is a natural oil product containing tasmanone as the active constituent. The Company operates in one business segment, being the conduct of research and development activities in the agricultural sector.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BGT BGT Shareholder Newsletter and Teleconference27/03/19
BGT Change of Director's Interest Notice - D Brumley04/03/19
BGT Change of Director's Interest Notice - R Klupacs28/02/19
BGT Appendix 4D - Half Yearly Report and Accounts - 31/12/18PRICE SENSITIVE20/02/19
BGT Appendix 4C - 31 December 2018PRICE SENSITIVE31/01/19
BGT BIO-GENE EXPANDS RESEARCH PROGRAM FOR QCIDEPRICE SENSITIVE13/12/18
BGT Change of Director's Interest Notice - P May06/12/18
BGT Change of Director's Interest Notice - R Jagger06/12/18
BGT Appendix 3B06/12/18
BGT Expiry of Listed Options20/11/18
BGT Results of Meeting - 2018 AGM20/11/18
BGT 2018 AGM - CEO Presentation20/11/18
BGT Appendix 4C - 30 September 2018PRICE SENSITIVE25/10/18
BGT Notice of Annual General Meeting/Proxy Form16/10/18
BGT Change of Registered Office15/10/18
BGT Company Update Presentation - October 201815/10/18
BGT IMPROVED MANUFACTURING PROCESS FOR FLAVOCIDEPRICE SENSITIVE11/10/18
BGT POSITIVE RESULTS FROM 28-DAY TOXICOLOGY STUDY ON FLAVOCIDEPRICE SENSITIVE09/10/18
BGT Appendix 3B - Release of Shares from Escrow02/10/18
BGT Change of Registry Address: Automic P/L - Sydney Office28/09/18
BGT Upcoming Release of Shares from Escrow14/09/18
BGT POSITIVE RESULTS FOR FLAVOCIDE IN INITIAL FIELD TESTINGPRICE SENSITIVE12/09/18
BGT POSITIVE EFFICACY RESULTS FOR FLAVOCIDE IN NEW PEST TYPESPRICE SENSITIVE05/09/18
BGT BGT 2018 Corporate Governance Statement23/08/18
BGT Appendix 4G - 201823/08/18
BGT BGT 2018 Appendix 4E and Annual ReportPRICE SENSITIVE23/08/18
BGT Appendix 3B - Release of Shares from Escrow26/07/18
BGT Appendix 4C - 30 June 2018PRICE SENSITIVE26/07/18
BGT POSITIVE RESULTS FOR FLAVOCIDE IN SAFETY STUDYPRICE SENSITIVE23/07/18
BGT BIO-GENE SUBMITS TWO NEW INTERNATIONAL PATENT APPLICATIONSPRICE SENSITIVE10/07/18
BGT Qcide advancement - new results and research collaborationPRICE SENSITIVE03/07/18
BGT Upcoming Release of Shares from Escrow29/06/18
BGT Appendix 3B - Release of Shares from Escrow29/06/18
BGT EXPANSION OF FLAVOCIDE MODE OF ACTION STUDIESPRICE SENSITIVE26/06/18
BGT BEE SAFETY STUDY DELIVERS POSITIVE FINDINGS FOR FLAVOCIDEPRICE SENSITIVE18/06/18
BGT Upcoming Release of Shares from Escrow13/06/18
BGT POSITIVE RESULTS WITH FLAVOCIDE VS. GRAIN STORAGE PESTSPRICE SENSITIVE28/05/18
BGT UPCOMING RELEASE OF SHARES FROM ESCROW11/05/18
BGT Appendix 4C - 31 March 2018PRICE SENSITIVE30/04/18
BGT POSITIVE EFFICACY TEST AGAINST ANOTHER MAJOR CROP PESTPRICE SENSITIVE26/04/18
BGT MANUFACTURING PROJECT WITH CSIRO ADVANCES TO STAGE 3PRICE SENSITIVE17/04/18
BGT POSITIVE RESULT IN EFFICACY TEST WITH MAJOR CEREAL CROP PESTPRICE SENSITIVE09/04/18
BGT Appendix 3B - Release of Shares from Escrow27/03/18
BGT POSITIVE RESULTS FOR FLAVOCIDE WITH MAJOR RICE PESTPRICE SENSITIVE26/03/18
BGT Bio-Gene Investor Conference Call - 26 March 201823/03/18
BGT ANIMAL HEALTH TESTING AND COLLABORATION UPDATEPRICE SENSITIVE21/03/18
BGT Appendix 3B - Loyalty Options08/03/18
BGT UPCOMING RELEASE OF SHARES FROM ESCROW07/03/18
BGT Prospectus for Loyalty Options Lodged01/03/18
BGT Letter to Optionholders01/03/18
BGT Letter to Ineligible Shareholders01/03/18
BGT Appendix 3B - Loyalty Options01/03/18
BGT Prospectus for Loyalty OptionsPRICE SENSITIVE01/03/18
BGT Appendix 3B23/02/18
BGT LOYALTY OPTIONS UPDATE20/02/18
BGT KEY APPOINTMENTS TO ADVISORY & MANAGEMENT TEAMS14/02/18
BGT Appendix 4D - Half Yearly Report and Accounts - 31/12/17PRICE SENSITIVE08/02/18
BGT UPCOMING RELEASE OF SHARES FROM ESCROW06/02/18
BGT Pilot study shows Flavocide activity against mosquitosPRICE SENSITIVE31/01/18
BGT Appendix 4C - December 2017PRICE SENSITIVE30/01/18
BGT BIO-GENE 2018 GOALS & OBJECTIVES FOLLOWING SUCCESSFUL IPOPRICE SENSITIVE21/12/17
BGT BIO-GENE ANNOUNCES POSITIVE SAFETY RESULTSPRICE SENSITIVE19/12/17
BGT BIO-GENE REPORTS POSITIVE INITIAL EFFICACY RESULTSPRICE SENSITIVE11/12/17
BGT BIO-GENE APPOINTS MR DOUG RATHBONE AS AN ADVISOR04/12/17
BGT Appendix 3B04/12/17
BGT BIO-GENE EXTENDS RESEARCH COLLABORATION WITH QDAF01/12/17
BGT BIO-GENE EXTENDS RESEARCH COLLABORATION WITH CSIROPRICE SENSITIVE30/11/17
BGT BIO-GENE COMPLETES $7.1M IPO TO LIST ON ASX29/11/17
BGT Becoming a substantial holder29/11/17
BGT Bio-Gene Investor Briefing29/11/17
BGT Initial Director's Interest Notice - P May29/11/17
BGT Initial Director's Interest Notice - K Rumble29/11/17
BGT Initial Director's Interest Notice - R Klupacs29/11/17
BGT Initial Director's Interest Notice - R Jagger29/11/17
BGT Initial Director's Interest Notice - D Brumley29/11/17
BGT Corporate Governance Statement28/11/17
BGT Updated Top 2028/11/17
BGT Company Pre-Quotation Disclosure27/11/17
BGT Securities Trading Policy27/11/17
BGT Pro-Forma Statement of Financial Statement27/11/17
BGT Loan Share Plan Rules27/11/17
BGT Full Year Audited Accounts 30 June 201727/11/17
BGT Full Year Audited Accounts 30 June 201627/11/17
BGT Top 2027/11/17
BGT Distribution Schedule27/11/17
BGT Constitution27/11/17
BGT Prospectus27/11/17
BGT Appendix 1A and Information Form and Checklist27/11/17
BGT Market Release - PQD27/11/17
BGT Market Release - AdmissionPRICE SENSITIVE27/11/17
BGT ASX Notice - Admission and Quotation27/11/17
BGT BGT Shareholder Newsletter and Teleconference
27/03/19
BGT Change of Director's Interest Notice - D Brumley
04/03/19
BGT Change of Director's Interest Notice - R Klupacs
28/02/19
BGT Appendix 4D - Half Yearly Report and Accounts - 31/12/18
20/02/19PRICE SENSITIVE
BGT Appendix 4C - 31 December 2018
31/01/19PRICE SENSITIVE
BGT BIO-GENE EXPANDS RESEARCH PROGRAM FOR QCIDE
13/12/18PRICE SENSITIVE
BGT Change of Director's Interest Notice - P May
06/12/18
BGT Change of Director's Interest Notice - R Jagger
06/12/18
BGT Appendix 3B
06/12/18
BGT Expiry of Listed Options
20/11/18
BGT Results of Meeting - 2018 AGM
20/11/18
BGT 2018 AGM - CEO Presentation
20/11/18
BGT Appendix 4C - 30 September 2018
25/10/18PRICE SENSITIVE
BGT Notice of Annual General Meeting/Proxy Form
16/10/18
BGT Change of Registered Office
15/10/18
BGT Company Update Presentation - October 2018
15/10/18
BGT IMPROVED MANUFACTURING PROCESS FOR FLAVOCIDE
11/10/18PRICE SENSITIVE
BGT POSITIVE RESULTS FROM 28-DAY TOXICOLOGY STUDY ON FLAVOCIDE
09/10/18PRICE SENSITIVE
BGT Appendix 3B - Release of Shares from Escrow
02/10/18
BGT Change of Registry Address: Automic P/L - Sydney Office
28/09/18
BGT Upcoming Release of Shares from Escrow
14/09/18
BGT POSITIVE RESULTS FOR FLAVOCIDE IN INITIAL FIELD TESTING
12/09/18PRICE SENSITIVE
BGT POSITIVE EFFICACY RESULTS FOR FLAVOCIDE IN NEW PEST TYPES
05/09/18PRICE SENSITIVE
BGT BGT 2018 Corporate Governance Statement
23/08/18
BGT Appendix 4G - 2018
23/08/18
BGT BGT 2018 Appendix 4E and Annual Report
23/08/18PRICE SENSITIVE
BGT Appendix 3B - Release of Shares from Escrow
26/07/18
BGT Appendix 4C - 30 June 2018
26/07/18PRICE SENSITIVE
BGT POSITIVE RESULTS FOR FLAVOCIDE IN SAFETY STUDY
23/07/18PRICE SENSITIVE
BGT BIO-GENE SUBMITS TWO NEW INTERNATIONAL PATENT APPLICATIONS
10/07/18PRICE SENSITIVE
BGT Qcide advancement - new results and research collaboration
03/07/18PRICE SENSITIVE
BGT Upcoming Release of Shares from Escrow
29/06/18
BGT Appendix 3B - Release of Shares from Escrow
29/06/18
BGT EXPANSION OF FLAVOCIDE MODE OF ACTION STUDIES
26/06/18PRICE SENSITIVE
BGT BEE SAFETY STUDY DELIVERS POSITIVE FINDINGS FOR FLAVOCIDE
18/06/18PRICE SENSITIVE
BGT Upcoming Release of Shares from Escrow
13/06/18
BGT POSITIVE RESULTS WITH FLAVOCIDE VS. GRAIN STORAGE PESTS
28/05/18PRICE SENSITIVE
BGT UPCOMING RELEASE OF SHARES FROM ESCROW
11/05/18
BGT Appendix 4C - 31 March 2018
30/04/18PRICE SENSITIVE
BGT POSITIVE EFFICACY TEST AGAINST ANOTHER MAJOR CROP PEST
26/04/18PRICE SENSITIVE
BGT MANUFACTURING PROJECT WITH CSIRO ADVANCES TO STAGE 3
17/04/18PRICE SENSITIVE
BGT POSITIVE RESULT IN EFFICACY TEST WITH MAJOR CEREAL CROP PEST
09/04/18PRICE SENSITIVE
BGT Appendix 3B - Release of Shares from Escrow
27/03/18
BGT POSITIVE RESULTS FOR FLAVOCIDE WITH MAJOR RICE PEST
26/03/18PRICE SENSITIVE
BGT Bio-Gene Investor Conference Call - 26 March 2018
23/03/18
BGT ANIMAL HEALTH TESTING AND COLLABORATION UPDATE
21/03/18PRICE SENSITIVE
BGT Appendix 3B - Loyalty Options
08/03/18
BGT UPCOMING RELEASE OF SHARES FROM ESCROW
07/03/18
BGT Prospectus for Loyalty Options Lodged
01/03/18
BGT Letter to Optionholders
01/03/18
BGT Letter to Ineligible Shareholders
01/03/18
BGT Appendix 3B - Loyalty Options
01/03/18
BGT Prospectus for Loyalty Options
01/03/18PRICE SENSITIVE
BGT Appendix 3B
23/02/18
BGT LOYALTY OPTIONS UPDATE
20/02/18
BGT KEY APPOINTMENTS TO ADVISORY & MANAGEMENT TEAMS
14/02/18
BGT Appendix 4D - Half Yearly Report and Accounts - 31/12/17
08/02/18PRICE SENSITIVE
BGT UPCOMING RELEASE OF SHARES FROM ESCROW
06/02/18
BGT Pilot study shows Flavocide activity against mosquitos
31/01/18PRICE SENSITIVE
BGT Appendix 4C - December 2017
30/01/18PRICE SENSITIVE
BGT BIO-GENE 2018 GOALS & OBJECTIVES FOLLOWING SUCCESSFUL IPO
21/12/17PRICE SENSITIVE
BGT BIO-GENE ANNOUNCES POSITIVE SAFETY RESULTS
19/12/17PRICE SENSITIVE
BGT BIO-GENE REPORTS POSITIVE INITIAL EFFICACY RESULTS
11/12/17PRICE SENSITIVE
BGT BIO-GENE APPOINTS MR DOUG RATHBONE AS AN ADVISOR
04/12/17
BGT Appendix 3B
04/12/17
BGT BIO-GENE EXTENDS RESEARCH COLLABORATION WITH QDAF
01/12/17
BGT BIO-GENE EXTENDS RESEARCH COLLABORATION WITH CSIRO
30/11/17PRICE SENSITIVE
BGT BIO-GENE COMPLETES $7.1M IPO TO LIST ON ASX
29/11/17
BGT Becoming a substantial holder
29/11/17
BGT Bio-Gene Investor Briefing
29/11/17
BGT Initial Director's Interest Notice - P May
29/11/17
BGT Initial Director's Interest Notice - K Rumble
29/11/17
BGT Initial Director's Interest Notice - R Klupacs
29/11/17
BGT Initial Director's Interest Notice - R Jagger
29/11/17
BGT Initial Director's Interest Notice - D Brumley
29/11/17
BGT Corporate Governance Statement
28/11/17
BGT Updated Top 20
28/11/17
BGT Company Pre-Quotation Disclosure
27/11/17
BGT Securities Trading Policy
27/11/17
BGT Pro-Forma Statement of Financial Statement
27/11/17
BGT Loan Share Plan Rules
27/11/17
BGT Full Year Audited Accounts 30 June 2017
27/11/17
BGT Full Year Audited Accounts 30 June 2016
27/11/17
BGT Top 20
27/11/17
BGT Distribution Schedule
27/11/17
BGT Constitution
27/11/17
BGT Prospectus
27/11/17
BGT Appendix 1A and Information Form and Checklist
27/11/17
BGT Market Release - PQD
27/11/17
BGT Market Release - Admission
27/11/17PRICE SENSITIVE
BGT ASX Notice - Admission and Quotation
27/11/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.6¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.859M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 955 3.7¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 78000 2
View Market Depth
Last trade - 16.12pm 21/11/2024 (20 minute delay) ?
BGT (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.